GCGR and Glucose intolerance: Retratrutide (LY3437943), a novel triple GLP-1, GIP, and glucagon receptor agonist, has a greater insulinotropic effect from both GIP and GLP-1 receptors than the glucose intolerance induced by the glucagon receptor [183].